This article was originally published in The Gray Sheet
Executive SummaryPremarket approval application submitted for the Screen automated cervical cancer detection system, the company reports July 6. Autocyte is seeking a primary screening indication for the device, which is intended for use with the Prep liquid sample preparation system ("The Gray Sheet" July 6, p. 14), for which a PMA is pending
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.